期刊
ACTA DERMATO-VENEREOLOGICA
卷 99, 期 3, 页码 298-303出版社
ACTA DERMATO-VENEREOLOGICA
DOI: 10.2340/00015555-3086
关键词
JAK inhibitor; chronic itch; psoriasis; scratching; IL-31
类别
资金
- Pfizer grant [W1203521]
- National Institutes of Health [AR063228]
- Uehara Memorial Foundation
- Japanese Society of Allergology
- Lois Pope LIFE Fellows Program
The Janus kinase 1/3 inhibitor tofacitinib has demonstrated an antipruritic effect in two phase III studies in psoriasis. However, the mechanisms behind this antipruritic effect are still unknown. We presently investigated whether tofacitinib affects spontaneous itch as well as expression of itch-related cytokines and epidermal nerve fiber density (ENFD) in the imiquimod- induced mouse model of psoriasis. Psoriasis-like skin lesions were produced by daily topical application of imiquimod to the back skin. Imiquimod treatment resulted in spontaneous scratching, which was significantly inhibited by tofacitinib treatment. Imiquimod treatment significantly increased mRNA expression of I122, I123, and I131, reduced peptidergic ENFD, and increased nonpeptidergic ENFD compared to naive mice. Tofacitinib significantly decreased the expression of those cytokines and increased peptidergic ENFD without a significant effect on nonpeptidergic ENFD. Tofacitinib may inhibit psoriatic itch through inhibition of cytokine expression as well as modulation of epidermal innervation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据